Novo Nordisk to license experimental GLP-1 pill from China's Hengrui

How the coverage leans

Across 5 sources · syndicated copies counted once

The coverage

1. China's Hengrui licenses weight-loss drug to Denmark's Novo Nordisk in deal worth up to $2.6B

   aa.com.tr · 35mShare

2. Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui

   seekingalpha.com · 3hShare

3. Novo Nabs Oral Obesity Drug From Hengrui in $2.6 Billion Deal

   bloomberg.com · 3hShare